Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04681040 · ClinicalTrials.gov registry record
Risk Stratification of COVID-19 Using Urine Biomarkers
A clinical trial of COVID-19 and Biomarker, sponsored by National Center for Global Health and Medicine, Japan.
- Active
- Registry status
- 964
- Enrollment target
- 7
- Study locations
NCT04681040: Active study of COVID-19 and Biomarker, sponsored by National Center for Global Health and Medicine, Japan.
NCT04681040 is a study of COVID-19 and Biomarker that is active but no longer recruiting, run by National Center for Global Health and Medicine, Japan. The registered enrollment target is 964 participants, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04681040, a study of COVID-19 and Biomarker, is active but no longer recruiting, sponsored by National Center for Global Health and Medicine, Japan.
- ACTIVE NOT RECRUITING
- Registry status
- 964 participants
- Enrollment target
- 7
- Study locations
Study Summary
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in infected patients, it produces symptoms which range from completely asymptomatic to those expressing severe illness. Early recognition of those developing severe manifestations allows for rapid and appropriate intervention, including admission to intensive care unit and intensive care therapy, such as mechanical ventilation. A current problem is that only limited data exist predicting the clinical course of COVID-19. This study will determine whether non-invasive urinalysis is useful in assessing and predicting the severity or clinical course of patients with COVID-19.
Conditions Studied
Study Locations (7)
Other
- Danish National Biobank - Copenhagen
- Unilab Group - Manila
Maryland
- MD Mount Sinai - Baltimore
São Paulo
- Hospital das Clinicas Ribeirao Preto - Ribeirão Preto
Kanagawa
- Shonan General Hospital - Kamakura
Tokyo
- National Center Global Health and Medicine - Shinjuku
Yamanashi
- Yamanashi Prefectural Central Hospital - Kofu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 964 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2024-03-25 |
What the registry record for NCT04681040 still lists
NCT04681040 is an observational study that tracks outcomes without assigning an intervention. The registered 964 participants enrollment target is mid-sized for trials with a published cap, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT04681040 lists 7 locations in 6 states (Other, Maryland, São Paulo).
Frequently Asked Questions
What is clinical trial NCT04681040 about?
NCT04681040 is a clinical study titled "Risk Stratification of COVID-19 Using Urine Biomarkers". Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in infected patients, it produces symptoms which range from completely asymptomatic to those expressing severe illness. Early recognition of those developing severe manifestations allows...
What is the current status of trial NCT04681040?
This trial is currently active not recruiting. The enrollment target is 964 participants. The study started on 2020-09-15. Estimated completion is 2024-03-25.
What conditions does trial NCT04681040 study?
This clinical trial studies the following conditions: COVID-19, Biomarker, Urine, Acute Respiratory Failure With Hypoxia.
Who is sponsoring clinical trial NCT04681040?
This trial is sponsored by National Center for Global Health and Medicine, Japan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04681040 being conducted?
This trial has 7 study locations across Maryland, São Paulo, Kanagawa, Tokyo, Yamanashi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04681040's enrollment target sits among peer trials
964 81st of 298 higher than 218 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI